A Randomised Controlled Trial Of Aetiology Based Antiemetic Guidelines For Reducing Nausea In Advanced Cancer Patients.
Funder
National Health and Medical Research Council
Funding Amount
$1,152,116.00
Summary
Nausea is a problem that can be very distressing to patients, and one that is difficult to assess and manage in patients with advanced cancer due to its multiple potential causes for this group. This study aims to test the effectiveness of an intervention which uses available anti-nausea medication specifically targeted to the likely cause of nausea for that individual to reduce the severity and impact of the symptom. It also tests second line medicatioins where nausea is unrelieved.
Dietary Intake Of Highly Processed Foods As A Contributor To Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$558,953.00
Summary
Modern food processing imparts desirable functional properties such as emulsification and longer shelf life. These biochemical modifications in our food may cause the body to turn on itself and destroy the cells which produce the sugar storage hormone insulin. This is important for survival and characterizes childhood onset diabetes and can also be seen in type 2 diabetes. This research will test some dietary and pharmaceutical interventions to slow the development of diabetes.
Improving Sexual Health In Men With Prostate Cancer: Randomised Controlled Trial Of Exercise And Psychosexual Therapies
Funder
National Health and Medical Research Council
Funding Amount
$583,416.00
Summary
Sexual dysfunction is one of the most common and distressing side effects of prostate cancer. Despite being a critical survivorship care issue, there is a clear gap in knowledge surrounding the optimal treatment of sexual dysfunction in men with prostate cancer. This project examines whether exercise aids in the management of sexual dysfunction and explores if an integrated treatment model incorporating pharmacological, exercise and psychosexual therapies maximises improvement in sexual health.
Identifying The Missing Heritability Of Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$461,104.00
Summary
One of the strongest risk factors for the development of breast cancer is having a close relative with the disease. Some advances have been made in understanding the specific genetic factors that underlie this susceptibility but these known genetic factors only explain about a third of the overall familial effects. This research will utilise our prior research, international research resources, new technology and supercomputing to identify the majority of genetic factors associated with breast c ....One of the strongest risk factors for the development of breast cancer is having a close relative with the disease. Some advances have been made in understanding the specific genetic factors that underlie this susceptibility but these known genetic factors only explain about a third of the overall familial effects. This research will utilise our prior research, international research resources, new technology and supercomputing to identify the majority of genetic factors associated with breast cancer susceptibility.Read moreRead less
The Role Of Aspirin In The Prevention Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,725,799.00
Summary
ASPREE is a large, phase 3 clinical study of health participants over the age of 70 years who have been randomized to either continuous low dose aspirin or placebo for an average of 5 years. This grant is concerned with collecting long-term follow-up for an additional 5 years, especially for evidence of colorectal cancer (CRC) as well as the exploration of potential mechanisms of action by which aspirin may prevent the development of CRC.
Investigating Signalling Pathways That Mediate Suppression Of Anoikis By Chemokine Receptors In Metastatic Breast Cancer Cells
Funder
National Health and Medical Research Council
Funding Amount
$597,349.00
Summary
This research aims at understanding the "nuts and bolts" of the main killer in cancer patients - tumour metastasis. We will look for molecules that are specific to metastatic tumour cells that transmit signals from the cell surface to the cell "suicide" machinery and prevent metastatic cancer cell death.
Tracking The Origins And Drivers Of Metastasis In Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,022,600.00
Summary
Prostate cancer is now the most commonly diagnosed cancer but only 10% of men with it, will die from it. Our current ability to discriminate between cancers with an indolent course and those that are lethal is poor. This project will examine the mixture of tumour clones (subclones) that are present in prostate cancers and define and track those cancer subclones that break away from the prostate and lodge in distant sites, causing death.
A Targeted Drug Delivery System For Treatment Of Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$243,607.00
Summary
The most common site where cancer spreads is the bone. Once it happens, it can dramatically affect patient’s quality of life and chance of survival. Current treatments are mostly palliative or associate with acute side effects due to systematic administration of anticancer drugs and their inability to selectively target the diseased area. This study aims to develop a nanocarrier that can uptake, protect and deliver anticancer drugs to the affected site in bone.
Effectiveness And Cost-effectiveness Of Systematic Screening For Lynch Syndrome (LS) In Australia
Funder
National Health and Medical Research Council
Funding Amount
$485,762.00
Summary
Lynch syndrome (LS) is an inherited condition that puts people at an increased risk of developing a range of cancers. We will use a detailed simulation model to evaluate the potential health benefits of testing new cases of colorectal, endometrial and ovarian cancers for LS, and whether this would be cost-effective. The aim is to identify LS-related cancer cases, so family members can be offered LS testing, and individuals found to have LS can be offered close observation/preventative surgery.
Characterising The Mutations, Signatures, Potential New Therapeutic Targets And Biomarkers In Malignant Mesothelioma Using Whole Genome Analysis.
Funder
National Health and Medical Research Council
Funding Amount
$1,219,288.00
Summary
Malignant mesothelioma is an aggressive tumour that occurs principally in the pleura as a consequence of inhaling asbestos fibres. Currently there is no cure for malignant mesothelioma. Thus new therapeutic approaches are desperately needed. Such new approaches will require a detailed understanding of the genetic lesions of malignant mesothelioma. Therefore we will perform whole genome sequencing of a large cohort of malignant mesothelioma patients to identify mesothelioma-related alterations.